Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TU2218 |
Trade Name | |
Synonyms | TU-2218|TU 2218|NCE 401|NCE401|NCE-401 |
Drug Descriptions |
TU2218 inhibits VEGFR2 and TGFBR1 (ALK5), which potentially results in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 5538). |
DrugClasses | TGFBR1 inhibitor 16 VEGFR2 Inhibitor 37 |
CAS Registry Number | NA |
NCIT ID | C186379 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + TU2218 | Pembrolizumab TU2218 | 0 | 1 |
TU2218 | TU2218 | 0 | 1 |
TU2218 + unspecified PD-1 antibody | TU2218 unspecified PD-1 antibody | 0 | 1 |